“alnylam-pharmaceuticals” Archives

in
Entry Author Date Location
Bio Roundup: ICER Eyes Cost, Azar at HHS, Gates’s ALZ Cash & More 11/17/17 National
Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More 11/03/17 National
Bio Roundup: RNAi’s Big Day, CAR-T For Kids, Drugs From Fungi & More 09/22/17 National
Alnylam Data Puts a Nobel Discovery One Step Closer to Approved Drug 09/20/17 Boston
Eyeing a Comeback, Arrowhead Bets on New RNAi Delivery Tool 09/19/17 Wisconsin
Ex-Cubist CEO Bonney Emerges at Kaleido, Flagship’s Latest Microbiome Startup 09/18/17 Boston
Bio Roundup: RNAi Drama, Immunotherapy Data, Lasker Winners & More 09/08/17 National
On Eve of Big Data Reveal, Patient Death Stalls Alnylam Hemophilia Drug 09/07/17 Boston
As Key Data Loom, Nobel Winner Mello Reflects on RNAi “Sci-Fi” Story 09/06/17 Boston
GSK Hands Nerve Drug Back to Ionis as RNA Battle Heats Up 08/11/17 San Diego
Regulus Dumps Two Drugs, AstraZeneca Sends Back Another, Shares Fall 06/12/17 San Diego
Ionis Touts Phase 3 Win, But Safety Worries Cloud Nerve Drug Study 05/15/17 San Diego
The Medicines Co., Alnylam Take Plunge, Outline Big Test For Heart Drug 04/26/17 New York
Harvard’s Verdine Aims to Retire, Become Full-Time FogPharma CEO 02/23/17 Boston
Biotech Leaders Sign Letter Condemning Trump’s Travel Ban 02/07/17 National
Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay 01/13/17 National
14 for ’17: Key Clinical Data To Watch For Next Year (Part 2) 12/22/16 National
ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More 12/06/16 National
Bio Roundup: Trump’s Rx Silence, PCSK9 News, Amgen’s Migraines & More 11/18/16 National
Regeneron: It’s Still Wait Until 2017 For Big Heart Drug Study 11/17/16 New York
With New Data, Medicines Co. Takes Long-Lasting Heart Drug to Phase 3 11/15/16 New York
Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More 10/07/16 National
Intellia Execs Talk CRISPR’s Path Forward at Xconomy’s Oct. 20 Event 10/06/16 Boston
Alnylam Scraps RNAi Drug After Safety Problems, Shares Plunge 10/05/16 Boston
Taking Aim at Alexion, Ra Pharma Heads to IPO Queue 10/03/16 Boston
Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More 09/30/16 National
Bio Roundup: Mylan Grilled, Duchenne Kids Thrilled, Zuck-Chan & More 09/23/16 National
Seeking to Join Editas, Intellia, CRISPR Tx Makes Long Awaited IPO Push 09/12/16 Boston
Alnylam Advances RNAi Drug Results After Two Years of Treatment 07/01/16 Boston
Regulus Shares Crumble As FDA Halts Testing of Hepatitis C Drug 06/27/16 San Diego
Page 1 of 11 next page »